Supplemental material
Expert Review of Pharmacoeconomics & Outcomes Research
Volume 22, 2022 - Issue 5
Original Research
Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system
, 
, &
Manuel A. Espinozaa Health Technology Assessment Unit, Center of Clinical Research, Pontificia Universidad Católica de ChileSantiago, Chile;b Department of Public Health, Faculty of Medicine, Pontificia Universidad Católica de ChileSantiago, ChileCorrespondence[email protected]
https://orcid.org/0000-0001-9564-9512View further author information
https://orcid.org/0000-0001-9564-9512View further author information, & Anne Petersc Institute for Science and Innovation in Medicine, Faculty of Medicine Clínica Alemana, Universidad Del Desarrollo, Santiago, Chilehttps://orcid.org/0000-0003-4641-5837View further author information
https://orcid.org/0000-0003-4641-5837View further author information